MedTrace Logo

Nanowear Heart Failure Management Multi-sensor Algorithm

NCT03719079 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2026-04-09

No results posted yet for this study

Summary

The NanoSense study is a multi-center, prospective, non-randomized, observational, feasibility, non-significant risk study. The NanoSense study will enroll up to 500 subjects in up to 10 centers in order to collect data which includes at least 150 heart failure hospitalizations in participating subjects.The duration of the NanoSense study is expected to be 2 years. The study device is the Wearable Congestive Heart Failure Management System (WCHFS, also known as SimpleSENSE)

Conditions

Interventions

DEVICE

SimpleSENSE

The Nanosense study is observational only. No interventions will be triggered by the SimpleSense device

Sponsors & Collaborators

  • Milton S. Hershey Medical Center

    collaborator OTHER

  • Hackensack Meridian Health

    collaborator OTHER

  • Nanowear Inc.

    lead INDUSTRY

Principal Investigators

  • John P Boehmer, M.D. · Milton S. Hershey Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-21
Primary Completion
2021-03-22
Completion
2024-06-18
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03719079 on ClinicalTrials.gov